Cowen & Co. analyst Ritu Baral maintained a Buy rating on Alnylam Pharma (ALNY) today and set a price target of $120. The company’s shares closed last Monday at $80.69.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 21.2% and a 47.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alnylam Pharma with a $125 average price target, representing a 51.3% upside. In a report issued on August 26, Piper Jaffray also reiterated a Buy rating on the stock with a $142 price target.
See today’s analyst top recommended stocks >>
Based on Alnylam Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $219 million. In comparison, last year the company had a GAAP net loss of $164 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.